Results 101 to 110 of about 46,962 (257)

"Society of Hematologic Oncology (SOHO) State of the Art Updates and Next Questions"-Treatment of ALL. [PDF]

, 2018
The outcome of adult acute lymphoblastic leukemia (ALL) has substantially improved by adopting pediatric-inspired regimens, and approximately half of the patients are nowadays cured.
Chiaretti, S, Hoelzer, D, Jabbour, E
core   +1 more source

Pulmonary Vascular Endothelial Cells in Lung Diseases: Mechanisms, Therapeutic Strategies, and Future Directions

Cell Proliferation, EarlyView.
The pathogenic mechanisms of pulmonary vascular endothelial cells (VECs) in lung diseases and their multimodal therapeutic strategies. ABSTRACT Pulmonary vascular endothelial cells (VECs) are essential for the normal function of the lung, through maintaining vascular barrier integrity, regulating blood flow, and participating in inflammatory responses ...
Qianyue Liu, Hongshuai Zheng, Jing Liu, Ming Gao, Faquan Lin, Lin Liao   +5 more
wiley   +1 more source

Diazirines Beyond Photoaffinity Labeling: A Comprehensive Overview of Applications in Biological Sciences, Materials Chemistry, and NMR‐Spectroscopy

Angewandte Chemie, Volume 138, Issue 4, 22 January 2026.
Diazirines are three‐membered, nitrogen‐containing heterocycles that decompose under light or heat to generate carbenes. For the past two decades, they have served mainly as minimally invasive tags in photoaffinity labeling (PAL). More recently, their value as versatile carbene precursors has been recognized.
Dominik Schnalzer, Viktor Savic, Clemens Cziegler, Michael Schnürch, Marko D. Mihovilovic   +4 more
wiley   +2 more sources

First-line therapy of chronic myeloid leukemia – focus on dasatinib

Blood and Lymphatic Cancer: Targets and Therapy, 2012
Philip C AmreinHematology-Oncology, Massachusetts General Hospital, Boston, USAAbstract: Dasatinib is a broad spectrum, ATP-competitive, tyrosine kinase inhibitor with low nM activity against Bcr-Abl, Src, and other tyrosine kinases.
Amrein PC
doaj  

Dasatinib Produces Lengthy Remissions of Extramedullary Leukemia: A Retrospective Observational Study

European Journal of Haematology, EarlyView.
ABSTRACT Since 2004, patients receiving imatinib with relapse in non‐marrow sites were given dasatinib to preserve control of leukemic marrow. Remissions in CNS and other organs began to be reported and are continuously observed to present. With resistance to one BCR::ABL1 tyrosine kinase inhibitor and sensitivity to a dual BCR::ABL1/SRC inhibitor ...
I. Cunningham, R. A. Fisher, J. Yang, Y. Guo, U. Bommhardt   +4 more
wiley   +1 more source

Meta‐analysis of genetic mapping studies in mice reveals candidate epilepsy modifier genes that are outside the current drug development landscape

Epilepsia, EarlyView.
Abstract Objective Despite decades of development in anti‐seizure medications, ~30% of individuals remain refractory to all treatments, and none of the existing therapies are disease modifying. Identifying targets outside the current preclinical paradigm is critically important.
Giovanna L. Durante, Anna L. Tyler, Rod C. Scott, Amanda E. Hernan, J. Matthew Mahoney   +4 more
wiley   +1 more source

A Hanks‐type bacterial kinase, PknS, directly phosphorylates the alternative sigma factor EcfK to promote resistance to protist predation

The FEBS Journal, EarlyView.
The Xanthomonas citri Hanks‐type kinase PknS autophosphorylates and directly phosphorylates the alternative sigma factor EcfK at five residues. Besides the conserved residue T51 in the σ2 domain, phosphorylation of a residue in the linker between σ2 and σ4 is critical for EcfK activation by promoting its interaction with a positively charged pocket in ...
Lídia dos Passos Lima, Dev Sriranganadane, Daiane Laise da Silva, Natália C. Drebes Dörr, Enzo Breviglieri Sichi Mello, Caio Vinicius dos Reis, Rogério Ferreira Lourenço, José Felipe Teixeira da Silva Santos, Anita Salmazo, Brenno Wendler Miranda, Katlin B. Massirer, Rafael M. Couñago, Cristina E. Alvarez‐Martinez   +12 more
wiley   +1 more source

A physiologically‐based pharmacokinetic precision dosing approach to manage dasatinib drug–drug interactions

CPT: Pharmacometrics & Systems Pharmacology
Dasatinib, a second‐generation tyrosine kinase inhibitor, is approved for treating chronic myeloid and acute lymphoblastic leukemia. As a sensitive cytochrome P450 (CYP) 3A4 substrate and weak base with strong pH‐sensitive solubility, dasatinib is ...
Christina Kovar, Helena Leonie Hanae Loer, Simeon Rüdesheim, Laura Maria Fuhr, Fatima Zahra Marok, Dominik Selzer, Matthias Schwab, Thorsten Lehr   +7 more
doaj   +1 more source

Extensive pleural and pericardial effusion in chronic myeloid leukemia during treatment with dasatinib at 100 mg or 50 mg daily

Haematologica, 2011
Dasatinib is considered an effective drug in imatinib-resistant chronic myeloid leukemia. Although reported to be well-tolerated, severe events such as pleural or pericardial effusion have been reported at 140 mg daily.
Maria-Theresa Krauth, Susanne Herndlhofer, Maria-Theresa Schmook, Gerlinde Mitterbauer-Hohendanner, Ernst Schlögl, Peter Valent   +5 more
doaj   +1 more source

Castration-Resistant Prostate Cancer Bone Metastasis Response Measured by ¹⁸F-Fluoride PET After Treatment with Dasatinib and Correlation with Progression-Free Survival: Results from American College of Radiology Imaging Network 6687 [PDF]

, 2015
Evan Y. Yu, Fenghai Duan, Mark Muzi, Xuan Deng, Bennett B. Chin, Joshi J. Alumkal, Mary-Ellen Taplin, Jina Taub, Ben Herman, Celestia S. Higano, Robert K. Doot, Donna Hartfeil, Philip G. Febbo, David A. Mankoff   +13 more
openalex   +1 more source